REDONDO BEACH, CA (Marketwired Jan 31, 2017) SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article discussing AXIM® Biotechnologies Inc. s (OTCQB: AXIM) efforts to keep its drug development costs at a minimum. The average cost of developing a prescription drug is some $2.6 billion, according to the Tufts Center for the Study of Drug Development, which includes $1.4 billion in out-of-pocket costs and an estimated $1.2
http://bit.ly/2kN58ap
No comments:
Post a Comment